Doctors sometimes use it off-label for weight loss, but thats not its official approval
This article is part of the PlexusDx Education Hub, where we unpack GLP-1 therapies, weight management protocols, and the genetic factors behind every metabolic decision
The SELECT cardiovascular outcomes trial demonstrated that semaglutide reduced the risk of major adverse cardiovascular events (heart attack, stroke, or cardiovascular death) by 20% in patients with obesity and established cardiovascular disease
Theo khuyn co t Nhu cu dinh dng khuyn ngh (Recommended Dietary Allowance RDA), mt ngi trng thnh cn np 55 mcg selen mi ngy, ti a ha qu trnh sn xut glutathione peroxidase
and T.B.L., are employees of the AstraZeneca group of companies